Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptora melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion—from said tumourcell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalised and inhibits secretion from said tumour cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.

Abstract: A light source and the method for operating the same are disclosed. The light source includes first and second lasers, and first and second wavelength control assemblies. The lasers emit first and second light beams, respectively, at wavelengths that are determined by first and second wavelength control signals. First and second beam splitters split the first and second light beams, respectively, to create first and second sampling light beams. The first and second wavelength control assemblies receive sampling light beams and generate the first and second wavelength control signals such that the wavelengths of the first and second light beams differ by no more than a predetermined amount. The first and second wavelength control assemblies each include an absorption cell having a gas that has an optical absorption that varies with the wavelength of the first and second sampling light beams at wavelengths around the output wavelength of the light source.

Abstract: A light source and the method for operating the same are disclosed. The light source includes first and second lasers, and first and second wavelength control assemblies. The lasers emit first and second light beams, respectively, at wavelengths that are determined by first and second wavelength control signals. First and second beam splitters split the first and second light beams, respectively, to create first and second sampling light beams. The first and second wavelength control assemblies receive sampling light beams and generate the first and second wavelength control signals such that the wavelengths of the first and second light beams differ by no more than a predetermined amount. The first and second wavelength control assemblies each include an absorption cell having a gas that has an optical absorption that varies with the wavelength of the first and second sampling light beams at wavelengths around the output wavelength of the light source.

Abstract: An apparatus and method for measuring displacement includes a light beam directed to an interferometer core that splits the light beam into first and second component beams. The first component beam is directed to a diffraction grating at approximately a Littrow angle. A diffraction is received by the interferometer core and is combined with the second component beam. The combination of the first and second component beams is measured to determine displacement of the diffraction grating.

Abstract: The apparatus and method for preparing a polymeric structure from which a number of medical devices may be constructed is described. The structures are preferably formed from bioabsorbable materials using low temperature fabrication processes, whereby drugs or other bio-active agents are incorporated into or onto the device and degradation of the drugs or other agents during processing is minimized. The method includes preparing a solution of at least one bioabsorbable polymer and a solvent. The solution is then deposited onto a stage and converted into a structure. The solvent is evaporated from the structure. The dried solution forms a structure that is removed from the stage and further dried before being stored in an inert environment. Thereafter, a medical device such as a stent may be constructed from the structure.

Abstract: At least two discrete quarter wave plates are provided for use as plane mirrors or reflectors in a displacement measuring interferometer, where the plates share common or substantially common reflecting surface geometries. A plurality of geometrically matched discrete matched quarter wave plates reduces the amount of tilt between an input beam provided to, and an output measurement beam provided by, an interferometer, resulting in increased interferometer dynamic range.